Diarylalkanes as potent inhibitors of binuclear enzymes

Patent metadata

Field	Value
Publication number	US-11857657-B2
Application number	US-202017113193-A
Country	US
Kind code	B2
Filing date	Dec 7, 2020
Priority date	May 28, 2004
Publication date	Jan 2, 2024
Grant date	Jan 2, 2024

Abstract

The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compounds—diarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or more of diarylalkanes and/or diarylalkanols, which inhibit the activity of binuclear enzymes, particularly tyrosinase and which prevent melanin overproduction. The present invention also provides a method for inhibiting the activity of a binuclear enzyme, particularly tyrosinase and a method for preventing and treating diseases and conditions related to binuclear enzyme function. The present invention further includes a method for preventing and treating melanin overproduction and diseases and conditions of the skin related thereto. The method for preventing and treating diseases and conditions related to binuclear enzyme function and melanin overproduction is comprised of administering to a host in need thereof an effective amount of a composition comprising one or more diarylalkanes and/or diarylalkanols synthesized and/or isolated from one or more plants together with a pharmaceutically acceptable carrier.

First claim

The invention claimed is:

1. A method for treating skin pigmentation due to inflammatory conditions, the method comprising administering an effective amount of a composition comprising a compound, wherein the compound is of 1-(2,4,6-trihydroxyphenyl)-3-(3′-hydroxy-4′-methoxyphenyl)-1-propanol, 1,3-bis(2,4-dimethoxyphenyl)-propan-1,3-diol.

2. The method of claim 1 , wherein the administration lightens dark skin pigmentation, reduces skin dullness, evens skin tone or corrects skin discoloration.

3. The method of claim 1 , wherein the administration reduces signs of aging on the skin and reduces wrinkles associated with aging by neutralization of active oxygen species.

4. The method of claim 1 , wherein the administration inhibits synthesis of melanin.

Assignees

• Unigen Inc

Inventors

• Jia Qi
• Zhao Ji-Fu

Classifications

• A61K31/05

  Phenols {(cannabinoids A61K31/658)} · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K8/347 Primary

  Phenols · CPC title

• A61K8/31

  Hydrocarbons · CPC title

• A61K8/4973

  with oxygen as the only hetero atom · CPC title